

Lexagene Holdings Inc

06:00 07 May 2019

LexaGene is enabling faster, easier pathogen detection

- Transforming traditional pathogen detection through its patented platform
- Targeting vast and underserved multi-billion-dollar markets
- Projected revenue stream of approximately US\$240 million over three-year timeframe

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) is a biotechnology company that is pioneering the first fully-automated pathogen detection platform for use in diagnostics and sample analysis.

The key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The process is as simple as collecting a sample, loading it into the instrument using a preparation cartridge and pressing "go." The instrument is able to process multiple samples at a time, returning results within around one hour.

Currently, the main markets being targeted by LexaGene are the vast and underserved veterinary health and food safety industries, but the customizable nature of the technology means that it is applicable to any type of diagnostic industry.

"We're positioning our product as one that can be used across many industries," said CEO Dr Jack Regan in an interview with Proactive. "We can do this because we define our product as open access, meaning the end user has the ability to customize the genetic test that our instrument performs."

CEO Regan developed LexaGene's patented microfluidic system. Regan was a lead scientist in developing another instrument designed for biowarfare surveillance used by the US Department of Homeland Security, and a device for detecting respiratory pathogens from nasal swab samples.

Currently, most pathogen detection is done through cultures, which can be time-consuming and require special conditions in order to deliver accurate results. Take food safety as an example: if a pathogen is destroying crops, a difference of hours or days for results can represent millions of dollars in lost revenue.

Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US\$40 billion.

Inflection points


LexaGene's LX2 Beta prototype is almost ready for commercialization, according to CEO Regan, moving them one step closer to sales.

The LX2 Analyzer is designed for non-technical workers to use easily, whereas most instruments currently on the market require a skilled molecular biologist to operate the system. The flow-through instrument processes large sample volumes to increase the chance of detecting very rare pathogens. It also comes at a low cost per test, as the instrument

Price: C\$0.7

Market Cap: C\$49.38M

1 Year Share Price Graph



Share Information

Code: LXG

Listing: TSX-V

52 week High Low
C\$0.93 C\$0.50

Sector: Health Care, Equipment & Services

Website: www.lexagene.com

Company Synopsis:

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press 'go'.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

uses reagents stored in bulk reservoirs instead of cartridges with pre-embedded reagents.

"The open access aspect of the analyzer is extremely valuable because we're providing hardware and controls, but the customer has the choice to customize the test to look for what they want," said Regan in an interview.

"We're doing this because we can't do everything at once, but we want people to be able to buy the tech and be enabled."

In February 2019, a clinical study was conducted using LX Analyzer technology where over 100 canine urine tests were sampled. The LX Analyzer detected 100% of the pathogens present in samples and even found antibiotic resistance factors in some examples. The results are 97.5% comparable to a reference lab, only automated and faster.

When it comes to revenue projections, the company plans on an additive recurring revenue stream with an expanding installation base. The recurring revenue stream comes from the disposable sample preparation cartridge that offer around 97% gross margin per sample tested.

LexaGene is pricing each instrument at around US\$50,000. Total revenue over three years is projected to be over US\$240 million.

Investors looking for an exit strategy can rest assured with the knowledge that similar companies such as Handylab, Biofiore and Iquum were all acquired for hundreds of millions of dollars by industry heavyweights like Roche.

Outlook

The next frontier for the LX2 analyzer will be human pathogen detection. Previously, LexaGene reported successful detection of human foodborne pathogens such as E. coli and staphylococcus. Now the company is looking to expand its genotyping capabilities to determine how the human body will respond to certain drugs.

One such application is to understand how individuals react to cannabis-based products, a new area for LexaGene. A person's unique genetic makeup determines how well they react to certain drugs, otherwise known as genotyping. The company can take a cheek swab and analyze it for different variants that will help to understand the proper dose of cannabis or other pharmaceuticals necessary for treatment.

"The ability and ease with which our technology can be used in markets aside from veterinary diagnostics and food safety is often underappreciated," said Regan in a recent company statement. "Many of these markets have no regulatory hurdles, which in time will allow us to start selling our technology into a diverse set of laboratories.

"When we begin selling our commercial units, open-access sales will complement our veterinary diagnostics and food safety revenues nicely."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.